The Discounted Cash Flow (DCF) valuation of Supernus Pharmaceuticals Inc (SUPN) is (8.86) USD. With the latest stock price at 36.17 USD, the upside of Supernus Pharmaceuticals Inc based on DCF is -124.5%.
Note: valuation result may not be accurate due to the low predictability of business.
| Range | Selected | |
| WACC / Discount Rate | 5.1% - 6.5% | 5.8% |
| Long-term Growth Rate | 3.0% - 4.8% | 3.9% |
| Fair Price | (65.79) - (4.76) | (8.86) |
| Upside | -281.9% - -113.2% | -124.5% |